1. In Vivo
  2. >>Archive

Baxter Acquires Gambro, Becomes Integrated Renal Therapy Leader

Baxter’s offer of $4 billion for Swedish hemodialysis manufacturer Gambro may be one of the largest medtech acquisitions of the year, but Baxter CEO Bob Parkinson describes the deal as a bolt-on for Baxter’s existing market in renal therapy. Of course the magnitude of the deal makes it “an adjacency with a capital A”, Parkinson quipped.

Baxter International Inc.’s offer of $4 billion for Swedish hemodialysis manufacturer Gambro AB may be one of the largest medtech acquisitions of the year. [See Deal] Baxter CEO Bob Parkinson describes the deal as a bolt-on for an existing product space and well within Baxter’s announced strategy of growing its existing clinical markets. Of course the magnitude of the deal makes it “an adjacency with a capital A” Parkinson quipped in a conference call on December 4.

The dialysis industry has several segments divided between chronic and acute renal failure. The product segments include equipment for in-center hemodialysis, hospital-based dialysis, peritoneal dialysis, and an emerging market in home dialysis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.